Department of Epidemiology, School of Public Health, Southern Medical University (Guangdong Provincial Key Laboratory of Tropical Disease Research), Guangzhou, Guangdong, China.
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
J Clin Microbiol. 2017 Dec;55(12):3366-3373. doi: 10.1128/JCM.00865-17. Epub 2017 Sep 13.
A novel GII.17 norovirus variant caused major gastroenteritis epidemics in China in 2014 to 2016. To explore the host immune factors in selection of the emergence of this new variant, we characterized its antigenic relatedness with the GII.4 noroviruses that have dominated in China for decades. Through an enzyme-linked immunosorbent assay (ELISA) and a histo-blood group antigen (HBGA) blocking assay using sera from GII.4 and the GII.17 variant-infected patients, respectively, we observed limited cross-immune reactivity by the ELISA but little reactivity by the HBGA blocking assay between GII.4 norovirus and the new GII.17 variant. Our data suggest that, among other possible factors, GII.4-specific herd immunity had little role in the emergence of the new GII.17 variant. Thus, GII.17 may be an important active antigenic type or immunotype that needs to be considered for future vaccine strategies against human noroviruses.
一种新型的 GII.17 诺如病毒变异株在 2014 年至 2016 年期间引发了中国的重大胃肠炎疫情。为了探索宿主免疫因素在这种新变异株出现中的选择作用,我们对其与在中国流行了几十年的 GII.4 诺如病毒的抗原相关性进行了表征。通过酶联免疫吸附试验(ELISA)和使用来自 GII.4 和 GII.17 变异株感染患者的血清进行的组织血型抗原(HBGA)阻断试验,我们观察到 ELISA 之间的交叉免疫反应有限,但 HBGA 阻断试验之间的反应很少。我们的数据表明,在其他可能的因素中,GII.4 特异性群体免疫在新的 GII.17 变异株的出现中作用不大。因此,GII.17 可能是一种重要的活性抗原类型或免疫型,需要考虑用于未来针对人类诺如病毒的疫苗策略。